Tirzepatide acts on GIP and GLP-1 receptors, which are involved in appetite regulation, glucose metabolism, and insulin response.
For this reason, lower-dose tirzepatide may be considered as part of an individualized treatment plan focused on metabolic health.
However, the effects of a microdose may differ from those seen with standard therapeutic dosing, and individual response can vary.



